We’re hoping to excite you about our work and to introduce you to who we are as a research team dedicated to ending the HIV epidemic. In the future, you will find interviews with staff members and clinical trial participants, explanations of the science and logic behind our clinical trials, news about community events, and much more.
The AMP Study (also known as HVTN 704/HPTN 085) tests an experimental antibody against HIV. AMP stands for Antibody Mediated Prevention. Read more about the AMP Study
The University of Pennsylvania HIV Clinical Trials Unit (UPenn HIV CTU) is a leader in HIV prevention, research, and education.
The research mission of the UPENN Clinical Trials Unit is to develop and conduct scientific research studies that discover how to treat or prevent HIV infection. We value our diverse study volunteers and build local and global partnerships with communities, scientists, and policymakers. we strive to make our clinic volunteer-focused and friendly, understanding that our…
NIAID Director Anthony S. Fauci, M.D., explains why we need an HIV vaccine, the two main approaches to HIV vaccine development, and why the HVTN 702 launch is exciting.
Experts are “cautiously optimistic.” Drs. Larry Corey and Diane Havlir discuss what it will take to get to zero HIV infections worldwide at the Fortune Brainstorm Health conference, May 2nd, 2017. San Diego. © 2017 Time Inc. All rights reserved.